Loteprednol Etabonate Opthalmic Suspension for the Treatment of Dry Eye
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
This was a single-center, randomized, double-masked, placebo-controlled, parallel-group,
4-visit, CAE (Controlled Adverse Environment) study lasting approximately 4 weeks. Subjects
were randomized to receive loteprednol etabonate ophthalmic suspension, 0.5% or placebo
(vehicle of loteprednol etabonate ophthalmic suspension, 0.5%) and instructed to dose
bilaterally either TID or QID according to randomization.